EU/3/18/2081

About

On 19 November 2018, orphan designation (EU/3/18/2081) was granted by the European Commission to Pharma Gateway AB, Sweden, for 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid (also known as AG10) for the treatment of ATTR amyloidosis.

Key facts

Active substance
3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid
Disease / condition
Treatment of ATTR amyloidosis
Date of first decision
19/11/2018
Outcome
Positive
EU designation number
EU/3/18/2081

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Pharma Gateway AB
Johanneslundsvägen 2
194 61 Upplands Väsby
Sweden
Tel. +46 8 59077800
E-mail: info@pharmagateway.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating